Denitsa Tsaneva-Damyanova

Prof. Dr. Denitsa Tsaneva-Damyanova

Microbiology and virology, Medical University of Varna, Varna, Bulgaria
orcid

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
30 April 2023 in Life
Verified
Journal Article
Open access
PDF file
DTDenitsa Tsaneva-Damyanova
Denitsa Tsaneva-Damyanova
LGLora Hristova Georgieva
Lora Hristova Georgieva
Hepatitis D virus (HDV) is a satellite virus that causes the most aggressive form of all viral hepatitis in individuals already infected with HBV (hepatitis B virus). In recent years, there has been a negative trend towards an increase in the prevalence of chronic hepatitis D in Europe, especially among immigrant populations coming from regions endemic for the virus. The aim of this review is to analyse the current epidemiology of chronic HDV, routes of transmission, prevalent genotype, its management, prevention, fighting stigma and options for viral control in European countries, such as Bulgaria.

1 January 2020 in Biotechnology & Biotechnological Equipment
Verified
Journal Article
Open access
DTDenitsa Tsaneva-Damyanova
Denitsa Tsaneva-Damyanova
SARS-CoV-2 virus is responsible for the current COVID-19 pandemic, which has resulted in more than 2 million confirmed cases and 139,515 deaths in 213 countries, areas and territories as of 20th April 2020. Although reverse transcription polymerase chain reaction is the diagnostic test, screening studies for SARS-CoV-2 antibodies are essential for our extensive knowledge of the viral spread, formation of collective immunity, prophylaxis and treatment algorithms for the infection. We investigated 586 outpatients, for IgM and IgG antibodies, by their request in Varna and the region of northeastern Bulgaria. All of them were patients of medical diagnostic laboratory “STATUS”, Varna city. We used serological, immunochromatographic tests (rapid tests) at least seven days after suspected viral infection. Twenty-eight of the serum samples were SARS-CoV-2 Ab positive: 4.8% (95% CI: 3.2–6.9%, n = 28). IgM Ab only were detected in 1.0% (95% CI: 0.4–2.2%, n = 6), IgG Ab only in 1.2% (95% CI: 0.5–2.5%, n = 7) and both IgM/IgG Ab in 2.6% (95% CI: 1.5–4.2%, n = 15), from all of the tested individuals (n = 586). In order to understand how many people have contracted the virus, to strengthen our collective immunity and to be able to assess the risk, in the aftermath, it is essential to investigate (IgM/IgG) antibody titers.

15 October 2018 in Journal of IMAB – Annual Proceeding (Scientific Papers)
Verified
Journal Article
Open access
DTDenitsa Tsaneva-Damyanova
Denitsa Tsaneva-Damyanova
EGElitsa Golkocheva-Markova
Elitsa Golkocheva-Markova
NVNational Centre Of Infectious And Parasitic Diseases Nrl Hepatitis Viruses
National Centre Of Infectious And Parasitic Diseases Nrl Hepatitis Viruses
LILiliya Ivanova
Liliya Ivanova
TKTsvetelina Kostadinova
Tsvetelina Kostadinova
ZSZhivka Stoykova
Zhivka Stoykova

26 September 2018 in Journal of IMAB – Annual Proceeding (Scientific Papers)
Verified
Journal Article
Open access
TKTsvetelina Kostadinova
Tsvetelina Kostadinova
LILiliya Ivanova
Liliya Ivanova
IHIvaylo Hristov
Ivaylo Hristov
TTTatina T. Todorova
Tatina T. Todorova
ZSZhivka Stoykova
Zhivka Stoykova
DTDenitsa Tsaneva-Damyanova
Denitsa Tsaneva-Damyanova

26 September 2018 in Journal of IMAB – Annual Proceeding (Scientific Papers)
Verified
Journal Article
Open access
TKTsvetelina Kostadinova
Tsvetelina Kostadinova
LILiliya Ivanova
Liliya Ivanova
MBMilena Bozhkova
Milena Bozhkova
DTDenitsa Tsaneva-Damyanova
Denitsa Tsaneva-Damyanova
TTTatina Todorova
Tatina Todorova
ZSZhivka Stoykova
Zhivka Stoykova

31 December 2019 in Folia Medica
Verified
Journal Article
Open access
PDF file
DTDenitsa Tsaneva-Damyanova
Denitsa Tsaneva-Damyanova
LILiliya I. Ivanova
Liliya I. Ivanova
SNSilviya Pavlova Nikolova
Silviya Pavlova Nikolova
STSvetlana B. Todorova
Svetlana B. Todorova
TPTsvetelina K. Popova
Tsvetelina K. Popova
Introduction: Hepatitis B virus (HBV) is one of the most significant human pathogens responsible for a huge number of acute and chronic liver infectious diseases worldwide. Aim: To find the duration of post-vaccination immune response in individuals allocated to five age groups from 6 months to 20 years. Materials and methods: All tested subjects were born between 1999 and 2018 and therefore covered by the compulsory vaccination program against hepatitis B. For the serological marker anti-HBs Ab we investigated 449 serum samples taken from ambulatory people and patients of St Marina University Hospital in Varna. Results: A positive antibody response (anti-HBs Ab > 10 mIU/ml) was reported in 79.7% (n = 51) of the group of subjects up to one year old, in 70.0% (n = 196) of the subjects in the age range 1 year/1 month to 15 years, and in 39.3% (n = 33) of the subjects 15 years/1 month to 20 years old. Female sex had a better post-vaccination response than male sex with statistically significant relationship between sex and anti-HBs Ab titer (&chi;2 = 24.76, p <0.01). Conclusions: Regardless of the mass immunization against HBV in Bulgaria, the relative share of chronic HBV infections does not show a downward trend. Therefore, it is very important to study the duration of the post-vaccination immune response by demonstrating the anti-HBs antibodies and to apply a booster dose from the vaccine if needed.